FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Nasal Obstruction

Allegra-D (by Hoechst Marion Roussel), Approved March 1998
Treatment for nasal congestion due to seasonal allergy

Breathe Right (by CNS), Approved June 1996
Treatment for breathing difficulties due to deviated nasal septum

Nephropathy

Soliris (eculizumab) (by Alexion), Approved March 2007
For the treatment of PNH, aHUS and generalized Myasthenia Gravis

Neuroblastoma

Unituxin (dinutuximab) (by United Therapeutics), Approved March 2015
For the treatment of pediatrics with high-risk neuroblastoma

Neuroendocrine Carcinoma

Afinitor (everolimus) (by Novartis), Approved May 2011
For the treatment of advanced pancreatic neuroendocrine tumors

Sutent (sunitinib malate) (by Pfizer), Approved May 2011
For the treatment of pancreatic neuroendocrine tumors

Xermelo (telotristat ethyl) (by Lexicon Pharmaceuticals), Approved February 2017
For the treatment of carcinoid syndrome diarrhea

Neurologic Disorders

Northera (droxidopa) (by Chelsea Therapeutics), Approved February 2014
For the treatment of neurogenic orthostatic hypotension

Neuropathy

Lyrica (pregabalin) (by Pfizer), Approved December 2004
For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia

Lyrica (pregabalin) (by Pfizer), Approved June 2012
For the treatment of neuropathic pain associated with spinal cord injury

Neutropenia

Neutroval (tbo-filgrastim) (by Teva Pharmaceutical), Approved August 2012
For the reduction in the duration of severe chemotherapy-induced neutropenia

Non-Hodgkin's Lymphoma

Beleodaq (belinostat) (by Spectrum Pharmaceuticals), Approved July 2014
For the treatment of relapsed or refractory peripheral T-cell lymphoma

Bexxar (by Corixa), Approved June 2003
For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse

Intron A (interferon alfa-2b, recombinant) (by Schering-Plough), Approved December 1997
Treatment for non-Hodgkin's lymphoma

Revlimid (lenalidomide) (by Celgene), Approved December 2005
For the treatment of low- and intermediate-1-risk myelodysplastic syndromes

Revlimid (lenalidomide) (by Celgene), Approved June 2013
For the treatment of mantle cell lymphoma

Rituxan (by Biogen IDEC, Genentech), Approved November 1997
Treatment for non-hodgkin's lymphoma

Zevalin (ibritumomab tiuxetan) (by Biogen IDEC), Approved February 2002
For the treatment of non-Hodgkin's lymphoma

Zydelig (idelalisib) (by Gilead), Approved July 2014
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma

Non-Small Cell Lung Cancer

Abraxane (paclitaxel protein-bound particles for injectable suspension) (by Celgene), Approved October 2012
For the treatment of non-small cell lung cancer

Alecensa (alectinib) (by Roche), Approved December 2015
For the treatment of ALK-positive, metastatic non-small cell lung cancer

Alunbrig (brigatinib) (by Ariad Pharmaceuticals), Approved April 2017
For the treatment of advanced ALK-positive metastatic non-small cell lung cancer

Gilotrif (afatinib) (by Boehringer Ingelheim), Approved July 2013
For the treatment of metastatic non-small cell lung cancer with EGFR mutations

Hycamtin (topotecan hydrochloride) (by GlaxoSmithKline), Approved October 2007
For the treatment of small cell lung cancer

Iressa (gefitinib) (by AstraZeneca), Approved May 2003
For the second-line treatment of non-small-cell lung cancer

Keytruda (pembrolizumab) (by Merck), Approved October 2015
For the treatment of PD-L1 positive advanced non-small cell lung cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved March 2015
For the treatment of metastatic squamous non-small cell lung cancer

Photofrin (by QLT), Approved January 1998
Treatment for early-stage, microinvasive endobronchial non-small cell lung cancer

Portrazza (necitumumab) (by Eli Lilly), Approved November 2015
For the treatment of metastatic squamous non-small cell lung cancer

Tagrisso (osimertinib) (by AstraZeneca), Approved November 2015
For the treatment of EGFR T790M mutation positive non-small cell lung cancer

Tarceva (erlotinib, OSI 774) (by Genentech, OSI Pharmaceuticals), Approved November, 2004
For the treatment of advanced refractory metastatic non-small cell lung cancer

Tecentriq (atezolizumab) (by Genentech), Approved May 2016
For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer

Zykadia (ceritinib) (by Novartis), Approved April 2014
For the treatment of ALK+ metastatic non-small cell lung cancer